Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. more
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 10.01M | 15.64M | 12.32M | 5.45M | [{"date":"2020-12-31","value":63.97,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":78.74,"profit":true},{"date":"2023-12-31","value":34.82,"profit":true}] | |
Operating Income | (10.01M) | (15.64M) | (12.32M) | (5.45M) | [{"date":"2020-12-31","value":-1000539400,"profit":false},{"date":"2021-12-31","value":-1564094000,"profit":false},{"date":"2022-12-31","value":-1231530900,"profit":false},{"date":"2023-12-31","value":-544691900,"profit":false}] | |
Total Non-Operating Income/Expense | (341.00K) | (319.33K) | - | - | [{"date":"2020-12-31","value":-34100100,"profit":false},{"date":"2021-12-31","value":-31932800,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (10.35M) | (15.96M) | (12.25M) | (5.30M) | [{"date":"2020-12-31","value":-1034639500,"profit":false},{"date":"2021-12-31","value":-1596026800,"profit":false},{"date":"2022-12-31","value":-1224783400,"profit":false},{"date":"2023-12-31","value":-529601500,"profit":false}] | |
Income Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (10.35M) | (15.96M) | (12.25M) | (5.30M) | [{"date":"2020-12-31","value":-1034639500,"profit":false},{"date":"2021-12-31","value":-1596026800,"profit":false},{"date":"2022-12-31","value":-1224783400,"profit":false},{"date":"2023-12-31","value":-529601500,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (10.35M) | (15.96M) | (12.25M) | (5.30M) | [{"date":"2020-12-31","value":-1034639500,"profit":false},{"date":"2021-12-31","value":-1596026800,"profit":false},{"date":"2022-12-31","value":-1224783400,"profit":false},{"date":"2023-12-31","value":-529601500,"profit":false}] | |
EPS (Diluted) | (19.57) | (47.90) | (32.68) | (7.07) | [{"date":"2020-12-31","value":-1957,"profit":false},{"date":"2021-12-31","value":-4790.26,"profit":false},{"date":"2022-12-31","value":-3267.86,"profit":false},{"date":"2023-12-31","value":-707.45,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
DWTX | |
---|---|
Current Ratio | 7.27 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DWTX | |
---|---|
ROA (LTM) | 0.00% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DWTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DWTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
EV/R | 0.00 |
EV/Ebitda | NM |
Dogwood Therapeutics, Inc. (DWTX) share price today is $2.74
Yes, Indians can buy shares of Dogwood Therapeutics, Inc. (DWTX) on Vested. To buy Dogwood Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DWTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Dogwood Therapeutics, Inc. (DWTX) via the Vested app. You can start investing in Dogwood Therapeutics, Inc. (DWTX) with a minimum investment of $1.
You can invest in shares of Dogwood Therapeutics, Inc. (DWTX) via Vested in three simple steps:
The 52-week high price of Dogwood Therapeutics, Inc. (DWTX) is $23.5. The 52-week low price of Dogwood Therapeutics, Inc. (DWTX) is $1.62.
The price-to-earnings (P/E) ratio of Dogwood Therapeutics, Inc. (DWTX) is
The price-to-book (P/B) ratio of Dogwood Therapeutics, Inc. (DWTX) is 0.00
The dividend yield of Dogwood Therapeutics, Inc. (DWTX) is 0.00%
The market capitalization of Dogwood Therapeutics, Inc. (DWTX) is
The stock symbol (or ticker) of Dogwood Therapeutics, Inc. is DWTX